Page 132 - Read Online

Page 12 of 13 Fang et al. Cancer Drug Resist. 2025;8:42

8. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis
Primers. 2020;6:224. DOI PubMed PMC
9. Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Nat Genet. 2019;51:202-6. DOI PubMed PMC
10. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56-61. DOI PubMed
11. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in
non-small cell lung cancer. Science. 2015;348:124-8. DOI PubMed PMC
12. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med.
2014;371:2189-99. DOI PubMed PMC
13. Drilon A, Siena S, Dziadziuszko R, et al; trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated
analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:261-70. DOI PubMed PMC
14. Waliany S, Lin JJ. Taletrectinib: TRUST in the continued evolution of treatments for ROS1 fusion-positive lung cancer. J Clin Oncol.
2024;42:2622-7. DOI PubMed PMC
15. Li W, Xiong A, Yang N, et al. Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non–small cell lung cancer: the Phase
II TRUST-I study. J Clin Oncol. 2024;42:2660-70. DOI PubMed PMC
16. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217-23.
DOI PubMed
17. Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1
pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22:4585-93. DOI PubMed PMC
18. Ambrosini M, Rousseau B, Manca P, et al. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic
colorectal cancer. Ann Oncol. 2024;35:643-55. DOI PubMed
19. Hoadley KA, Yau C, Hinoue T, et al; Cancer Genome Atlas Network. Cell-of-origin patterns dominate the molecular classification of
10,000 tumors from 33 types of cancer. Cell. 2018;173:291-304.e6. DOI PubMed PMC
20. Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals
distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16:64. DOI PubMed PMC
21. Nielsen M, Lundegaard C, Blicher T, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B
locus protein of known sequence. PLoS One. 2007;2:e796. DOI PubMed PMC
22. Thorsson V, Gibbs DL, Brown SD, et al; Cancer Genome Atlas Research Network. The immune landscape of cancer. Immunity.
2018;48:812-30.e14. DOI PubMed PMC
23. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol.
2014;15:550. DOI PubMed PMC
24. Danaher P, Warren S, Dennis L, et al. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer. 2017;5:18. DOI
PubMed PMC
25. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS.
2012;16:284-7. DOI PubMed PMC
26. Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat
Rev Clin Oncol. 2021;18:35-55. DOI PubMed PMC
27. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of
genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23:4242-50. DOI PubMed PMC
28. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J
Med. 2016;375:819-29. DOI PubMed PMC
29. Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227-31.
DOI PubMed PMC
30. Fan Y, Song S, Li Y, et al. Galectin-3 cooperates with CD47 to suppress phagocytosis and T-cell immunity in gastric cancer peritoneal
metastases. Cancer Res. 2023;83:3726-38. DOI PubMed PMC
31. Krenz B, Gebhardt-Wolf A, Ade CP, et al. MYC- and MIZ1-dependent vesicular transport of double-strand RNA controls immune
evasion in pancreatic ductal adenocarcinoma. Cancer Res. 2021;81:4242-56. DOI PubMed PMC
32. Dhanasekaran R, Hansen AS, Park J, et al. MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible
through restoration of proinflammatory macrophages. Cancer Res. 2023;83:626-40. DOI PubMed PMC
33. Dou Y, Katsnelson L, Gritsenko MA, et al; Clinical Proteomic Tumor Analysis Consortium. Proteogenomic insights suggest druggable
pathways in endometrial carcinoma. Cancer Cell. 2023;41:1586-605.e15. DOI PubMed PMC
34. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231-5. DOI
PubMed 125